Syschem India Limited has successfully resolved a legal dispute with QP Pharmachem, marking a significant development for the company. The case, filed under Section 138 of the Negotiable Instruments Act, has been settled through a compromise between the parties.

Settlement Details

The settlement involves a total amount of ₹5.18 crore, with Syschem India having already paid a substantial portion. Here's a breakdown of the settlement:

Key Points of the Settlement

• Case Dismissal: Following the compromise between Syschem India and QP Pharmachem, the case has been dismissed as withdrawn.
• Contingent Payment: A cheque for ₹1,22,59,607 has been issued to QP Pharmachem as a contingent payment.
• Exchange Rate Provision: The contingent cheque will only be utilized if there are dollar exchange rate differences for remittance to an overseas entity in China.

Legal Proceedings

The case was heard in the Chief Judicial Magistrate - 1st Class, Taluka Court, Derabassi. The order was received by Syschem India on October 22, 2025.

Company Disclosure

Syschem India Limited has made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's filing includes details about the litigation, its resolution, and the financial impact on the company.

This settlement resolves a significant legal matter for Syschem India Limited, potentially allowing the company to focus on its core business operations moving forward.

Syschem (India) Limited , a pharmaceutical manufacturer, has announced a significant expansion of its production capabilities, focusing on antibiotics including amoxicillin. The company's board of directors has approved plans for both a new factory and the expansion of an existing unit, marking a substantial investment in its manufacturing infrastructure.

New Production Unit

The board has given the green light for setting up an additional production unit at the company's existing plant in Village Bargodam, Tehsil Kalka, District Panchkula, Haryana. This new facility will be dedicated to manufacturing key antibiotic products, including:

• Cloxacillin Sodium
• Dicloxacillin Sodium
• Flucloxacillin Sodium

Expansion of Existing Amoxicillin Unit

In addition to the new unit, Syschem (India) is set to expand its recently established amoxicillin production facility. This expansion aims to significantly increase the production capacity of amoxicillin, a widely used antibiotic.

Capacity and Investment Details

The company has provided detailed information about the expansion:

The existing plant operates at a maximum production capacity of 90%, with an average utilization of 77%.

Strategic Rationale

Syschem (India) cites several strategic reasons for this expansion:

1. Improving overall operational efficiency
2. Strengthening the product portfolio
3. Meeting growing customer demand
4. Increasing overall plant capacity

Market Impact

This expansion positions Syschem (India) to capitalize on the growing demand for antibiotics in the pharmaceutical market. The introduction of new antibiotic products alongside increased amoxicillin production capacity could potentially strengthen the company's market position in the antibiotic segment.

The company expects to commence commercial production from these new and expanded facilities by the end of December 2025. This move represents a significant step in Syschem (India)'s growth strategy, potentially enhancing its competitiveness in the pharmaceutical industry.